Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood in Allogeneic HSCT for Hematologic Malignancies
NCT00427557Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2006
- Primary completion
- Nov 2010
- Countries
- 1
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Hematopoietic Stem Cells
- Drugs
- umbilical cord blood
- Conditions
- graft-versus-host disease (GVHD)
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Engraftment at 100 days. Started Oct 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Cellular Therapy with Cord Blood Cells
Conditioning + UCB + Stem Cell Transplant
03
Who it enrols
Patients with advanced hematologic malignancies (MM, AML, MDS, ALL, NHL, HL, CLL) in >1st CR, age up to 80, with a 10/10 HLA-matched donor and available cord blood unit.
04
Endpoints
Primary
Number of Participants With Engraftment
Beyond the preview
Go deeper on NCT00427557.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427557.